TaxTMI Login
Just a moment...
Press 'Enter' to add multiple search terms. Rules for Better Search
When case Id is present, search is done only for this
of 
of 
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of of 
All Case Laws
of of All Case Laws
Note
Bookmark
Share
Don't have an account? Register Here
of <h1>CCI dismisses cartelization allegations against pharmaceutical companies in ESIC procurement due to insufficient evidence under Section 3(3)</h1> <h3>In Re: Vijay Halder, Ramesh, Chetan, Sandeep Gupta, Lakhvinder Singh (Nova Pharma), Rajan Shukhija (Hospimax Care Pvt. Ltd.), Deputy Medical Commissioner</h3> CCI dismissed cartelization allegations against pharmaceutical companies in ESIC medicine procurement tenders under Section 3(3) of Competition Act, 2002. ... Cartelization in respect of procurement of medicines by ESIC - contravention of provisions of Section 3(3) of Competition Act, 2002 - HELD THAT:- The Commission observes that there are numerous medicines and medical/healthcare products which are procured by ESIC and other government bodies. The Informant has not provided details of tenders/ medicines/ parties involved in the alleged conduct. Apart from making bald allegations, the Informant has not placed on record any cogent material to enable the Commission to examine the matter. Rather, the Informant failed to provide the requisite information in spite of being accorded two opportunities. The Commission finds that no prima facie case of contravention of the provisions of Section 3(3) of the Act is made out against any of the OPs in the instant matter. Accordingly, the information is ordered to be closed forthwith in terms of the provisions contained in Section 26(2) of the Act. Consequently, no case for grant for relief(s) as sought under Section 33 of the Act arises and the said request is rejected. Issues: Alleged cartelization in procurement of medicines by ESIC, Contravention of Section 3(3) of the Competition Act, 2002, Lack of evidence and details provided by the InformantAnalysis:The Information filed alleged cartelization in the procurement of medicines by ESIC, involving five individuals, ESIC officials, and pharmaceutical companies. The Informant claimed that this cartel arrangement led to inflated prices of medicines and healthcare products. The Informant also highlighted the lack of transparency in decision-making regarding guidelines and pricing structures, attributing the overpricing to collusion among the parties involved. The estimated overpricing was around 40%, resulting in significant financial losses. Additionally, the Informant pointed out that other government bodies also adopted ESIC prices as benchmarks, further exacerbating the impact of the alleged malpractice on public funds and accessibility to healthcare products.The Informant requested immediate investigation, cancellation of tenders, appointment of an investigation agency, and the formation of a committee to reevaluate pricing and introduce a new bidding system. Interim relief was sought in the form of initiating an inquiry, canceling tenders, appointing a monitoring committee, investigating alleged cartel masterminds, and establishing new pricing guidelines. The Commission reviewed the Information but found the details and material provided insufficient to substantiate the allegations. Despite multiple opportunities given to the Informant to provide necessary information, no response was received within the specified timelines.Subsequently, the Commission determined that no prima facie case of contravention of Section 3(3) of the Act was established against any of the Opposite Parties (OPs) based on the available record. As a result, the Information was ordered to be closed under Section 26(2) of the Act, and relief under Section 33 was denied. The Secretary was directed to communicate this decision to the Informant, concluding the matter based on the lack of evidence and failure to provide essential details by the Informant despite repeated opportunities.
TaxTMI 
TaxTMI 
